Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics
18 nov. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics Madrid and Barcelona (Spain) 18 November, 2021 – Algenex SL, a biotech company...
Commercial Adoption of Herdscreen® ASFV Antibody Test in Europe
28 oct. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Commercial Adoption of Herdscreen® ASFV Antibody Test in Europe New pen-side test allows for highly specific, sensitive detection of infected animals or contaminated pig-derived...
Algenex enters biocomponents market to provide mammalian-free production of cost efficient high-quality proteins and peptides
30 sept. 2021 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex enters biocomponents market to provide mammalian-free production of cost efficient high-quality proteins and peptides Proven technology poised to accelerate growth of emerging...
Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease
21 juin 2021 07h00 HE
|
Algenex SL
PRESS RELEASE Algenex and FATRO announce positive CVMP opinion for CrisBio-based vaccine for Rabbit Viral Haemorrhagic Disease Madrid (Spain) and Bologna (Italy), June 21, 2021 – Algenex SL, a...
Algenex inaugurates new facility with capacity to produce up to 100 million vaccine doses
24 sept. 2020 09h00 HE
|
Algenex SL
Algenex inaugurates new facility with capacity to produce up to 100 million vaccine doses New facility can support the production of up to 3.5kg of recombinant protein equivalent to around 100...
Algenex advances insect-based vaccine production technology in human health
05 mai 2020 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex advances insect-based vaccine production technology in human health CrisBio® offers efficient, economic and rapid response tool in pandemics. Madrid, May 5, 2020.- Algenex SL...
Algenex and FATRO sign commercial license agreement for development of a second CrisBio®-based vaccine
02 déc. 2019 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex and FATRO sign commercial license agreement for development of a second CrisBio®-based vaccine Agreement strengthens collaboration between the companies...
First Algenex CrisBio®-based vaccine submitted to European Medicines Agency
15 oct. 2019 02h00 HE
|
Algenex SL
PRESS RELEASE First Algenex CrisBio®-based vaccine submitted to European Medicines Agency Potential approval would validate the use of Algenex’ CrisBio® technology for the manufacture of...
Algenex and Global DX sign agreement to develop and commercialize diagnostic products for the detection of African Swine Fever
28 mai 2019 02h00 HE
|
Algenex SL
PRESS RELEASE Algenex and Global DX sign agreement to develop and commercialize diagnostic products for the detection of African Swine Fever Madrid (Spain) and Stirling (UK), May 28, 2019 –...
ALGENEX appoints new Strategic Advisory Board (SAB)
13 mars 2019 08h00 HE
|
Algenex SL
PRESS RELEASE ALGENEX appoints new Strategic Advisory Board (SAB) Advisors include recognized industry leaders in international healthcare Madrid (Spain), March 13, 2019 – ALGENEX SL (the...